Discover this podcast and so much more

Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

Should We Be Concerned About Resistance and Development of New Variants With COVID-19 Antiviral Therapy?

Should We Be Concerned About Resistance and Development of New Variants With COVID-19 Antiviral Therapy?

FromCCO Infectious Disease Podcast


Should We Be Concerned About Resistance and Development of New Variants With COVID-19 Antiviral Therapy?

FromCCO Infectious Disease Podcast

ratings:
Length:
7 minutes
Released:
Jan 4, 2023
Format:
Podcast episode

Description

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 treatments and the possibility for antiviral resistance, including:Treatment resistance mechanismsCOVID-19 testingCOVID-19 treatments, including antivirals and monoclonal antibodiesPresenters:Fernando Carnavali, MDAssociate Professor of MedicineDivision ChiefGeneral Internal MedicineDepartment of MedicineSite DirectorCOVID Center of Excellence Satellite-Ansonia Mount Sinai Health New York, New YorkRasika Karnik, MS, MDAssistant ProfessorDivision of Primary CareDepartment of Internal MedicineUniversity of ChicagoMedical DirectorPost-COVID Recovery ClinicChicago, IllinoisRenslow Sherer, MDDirectorInternational HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisJoseph Torrisi, PharmD, BCIDPClinical Pharmacy SpecialistInfectious Diseases PharmacyGrady Health SystemAtlanta, GeorgiaLink to slides: https://bit.ly/3hXMgIdLink to full program: https://bit.ly/3G271KL
Released:
Jan 4, 2023
Format:
Podcast episode

Titles in the series (100)

Weekly updates on new data and best practices in patient care for a variety of infectious diseases including COVID-19, HIV, and viral hepatitis, from Clinical Care Options. Gain practical strategies and earn CME/CE credit for selected episodes.